|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The urokinase-type plasminogen activator receptor (uPAR) has been implicated as a modulator of several biochemical processes that are active during tumor invasion and metastasis, e.g. extracellular proteolysis, cell adhesion, and cell motility.
|
17355965 |
2007 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
|
17545513 |
2007 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In addition to the uPA-uPAR system, matrix metalloproteinases (MMPs) are involved in tumor cell invasion and metastasis.
|
17657740 |
2007 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
|
16475674 |
2006 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Of the locally recurrent hormone-refractory tumours, 21% had an increased copy number of uPA, but no high-level amplifications were found; 31% of the metastases had increased copy number and one high-level amplification of the uPA.
|
16430655 |
2006 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Cancer invasion and metastasis are highly complex processes and a serine protease urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system has been postulated to play a central role in the mediation of cancer progression.
|
17075310 |
2006 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of MMP-2 mRNA was significantly correlated with lymph node metastasis (metastasis: 61.9%, no metastasis: 39.1%, chi(2) = 7.61, P<0.05), Lauren's classification of diffuse/mixed types: 54.2%, intestinal type: 26.3%, chi(2) = 4.25, P<0.05, expression of uPA and uPA-R mRNA (uPA+: 55.1%, uPA-: 22.2% and uPA-R+: 54.9%, uPA-R-: 18.8%, chi(2) = 5.72 and 6.40 respectively, P<0.05).
|
15929171 |
2005 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
These results suggest that at least one of the underlying mechanisms of BRMS1-dependent suppression of tumor metastasis includes inhibition of NF-kappaB activity and subsequent suppression of uPA expression in breast cancer and melanoma cells.
|
15867352 |
2005 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The results of this study indicated the possibility that cagA-positive H. pylori may play an important role not only in tissue remodeling, angiogenesis and wound healing but also in the process of degradation of the extracellular matrix breakdown, tumor invasion and metastasis by inducing uPA and uPAR complex in the gastric cancer cells.
|
16109653 |
2005 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
It is a specific cell surface receptor for its ligand, urokinase-type plasminogen activator, which catalyzes the formation of plasmin from plasminogen to generate the proteolytic cascade and leads to the breakdown of the extracellular matrix. uPAR has been shown to correlate with a propensity to tumor invasion and metastasis in several types of non-central nervous system tumors.
|
15894933 |
2005 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
CPL also down-regulated the expression of urokinase type plasminogen activator (uPA), one of key proteins associated with invasion and metastasis of tumor cells in a concentration dependent fashion, while CPL didn't significantly affect the expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) by reverse transcriptase-polymerase chain reaction (RT-PCR).
|
15635158 |
2005 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We have also demonstrated previously that transforming growth factor-beta1 (TGF-beta1) stimulates urokinase-type plasminogen activator (uPA)-dependent invasion and metastasis of HRA cells.
|
14597629 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
NF-kappaB-mediated expression of genes involved in angiogenesis (IL-8, VEGF), and invasion and metastasis (MMP9, uPA, uPA receptor) may further contribute to the progression of prostate cancer.
|
14689584 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Because uPA expression is strongly correlated with its hypomethylated state, we utilized the uPA gene in the highly invasive MDA-231 human breast cancer cells as a model system to test the hypothesis that pharmacological reversal of the uPA promoter hypomethylation would result in its silencing and inhibition of metastasis.
|
15150277 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Urokinase-type plasminogen activator (uPA) has been implicated in tumor cell invasion and metastasis.
|
14676209 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Because beta-catenin and its target genes urokinase-type plasminogen activator receptor (uPAR) and cyclin D1 are overexpressed in colon cancers, and are linked to cancer growth, invasion, and metastasis, we investigated whether DCA activates beta-catenin signaling and promotes colon cancer cell growth and invasiveness.
|
15004225 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
C4.4A, a structural homologue of the urokinase-type plasminogen activator receptor (uPAR), was originally identified as a metastasis-associated membrane protein, but little is known about its structural and functional properties.
|
15012588 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
We have previously reported in a series of papers that a Kunitz-type protease inhibitor, bikunin, suppresses up-regulation of urokinase-type plasminogen activator (uPA) and its specific receptor (uPAR) expression, phosphorylation of ERK1/2 and cancer cell invasion in vitro and peritoneal disseminated metastasis in vivo.
|
15168733 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Some of these genes were already known to be associated with apoptosis (BIK, TEGT, SSI-3), hypoxia-inducible genes (HIF1A, CA12), and tumor cell invasion and metastasis (CTSL, CTSB, PLAU, CD44).
|
15337562 |
2004 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Stromal cells also contribute to breast cancer growth and metastasis through the production of extracellular matrix (ECM) modifiers such as urokinase type plasminogen activator (uPA), its receptor (uPAR), its inhibitors (PAI-1 and PAI-2), matrix metalloproteinases (MMPs), and growth factors, including the fibroblast and insulin-like growth factors (FGF's and IGF's).
|
12574821 |
2003 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) is a factor in urokinase-type plasminogen activator proteolytic system, which is important for tumour invasion and metastasis.
|
12490312 |
2003 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Urokinase-type plasminogen activator (uPA) is a member of the serine protease family and can break down various components of the extracellular matrix to promote growth, invasion, and metastasis of several malignancies including breast cancer.
|
12198113 |
2002 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Urokinase-type plasminogen activator (uPA) is a serine protease that is causally involved in cancer progression, especially invasion and metastasis.
|
12023852 |
2002 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
As uPA can be involved in cancer invasion and metastasis, C/C genotype in exon 6 of uPA gene can be further considered as being related to colorectal cancer progression.
|
12430175 |
2002 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The role of urokinase-type plasminogen activator receptor (uPAR) in human colon cancer metastasis has not been tested using an antisense approach.
|
11291054 |
2001 |